MedTrace Logo

Pediatric Acute Kidney Injury in COVID-19

NCT04466306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-12-03

No results posted yet for this study

Summary

This study is an observational registry of children with or suspected to have SARS CoV2 (COVID-19) admitted to pediatric intensive care units (PICU). This registry will help describe the prevalence, rate and severity of acute kidney injury (AKI) in children with Severe Acute Respiratory Syndrome Coronavirus-2(SARS CoV2) across the world. The registry will be developed using a point prevalence methodology and then full retrospective review. Once a week, from April through June 2020, data collection will occur in "real-time" to estimate a weekly point prevalence of AKI and renal replacement therapy (RRT). The operational definition of "patients under investigation" (PUIs) will be used to identify the denominator of patients to be studied. The PUIs will be cohorted into SARS CoV2 test positive, test negative, test pending, or test unavailable. The primary aim of this study is to deliver a global, objective data driven analysis of the burden of AKI in virus positive patients or patients under investigation (PUI) who are admitted to the pediatric intensive care unit.

Conditions

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • Children's of Alabama

    collaborator OTHER

  • The Hospital for Sick Children

    collaborator OTHER

  • Children's Healthcare of Atlanta

    lead OTHER

Principal Investigators

  • Rajit K Basu, MD · Children's Healthcare of Atlanta

Eligibility

Min Age
7 Days
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-07-01
Completion
2021-07-01

Countries

  • United States
  • Canada
  • Israel
  • Japan
  • Serbia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466306 on ClinicalTrials.gov